Back to the Top
The following message was posted to: PharmPK
I am looking for clinical articles that support a claim of reduced
nephrotoxicity with pharmacy dosing services. Any help would be greatly
appreciated.
Thanks,
Jay Bryant-Wimp, RPh
Back to the Top
If you find it, please share with the rest of the world?
rga
Back to the Top
The following message was posted to: PharmPK Jay,
Here is a nice example of a study showing the benefits of a
pro-active pharmacy based PK service on aminoglycosides related
nephrotoxicity.
Van Lent-Evers, Mathot RAA, Geus WP, van Hout BA, Vinks AATMM. Impact
of goal-oriented, model-based TDM of aminoglycosides on clinical
outcome: a cost-effectiveness analysis. Ther Drug Monit 1999;21:63-73.
best regards,
Sander Vinks
Alexander A. Vinks, PharmD, PhD,
Research Professor of Pediatrics
Pharmacology Research Center & Clinical Trials Office
Children's Hospital Medical Center
3333 Burnet Avenue
Cincinnati, Ohio 45229-3039
Tel: (513) 636-0159; (513) 636-0160 (secretary).
Fax: (513) 636-0168.
CHMCC email: sander.vinks.aaa.chmcc.org
Back to the Top
Dear Jay:
You might look at van Lent-Evers, et al, "Impact of
Goal-Oriented and Model-Based Clinical Pharmacokinetic Dosing of
Aminoglycosides on Clinical Outcome: A Cost-Effectiveness Analysis",
Therap. Drug Monit. 21: 63-73, 1999. There are a bunch of other
references in that article.
Best regards,
Roger Jelliffe
Roger W. Jelliffe, M.D. Professor of Medicine, USC
USC Laboratory of Applied Pharmacokinetics
2250 Alcazar St, Los Angeles CA 90033, USA
Phone (323)442-1300, fax (323)442-1302, email= jelliffe.-at-.hsc.usc.edu
Our web site= http://www.usc.edu/hsc/lab_apk
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)